Member Info for Yorkshireboy

Continued: - Now to one area of mystery for some posters i.e. the collaboration with ‘VistaGen Therapeutics’. One poster said, ‘Vistagen sound like another useless lifestyle pharma that have ripped off their shareholders. They can't provide value to their own shareholders - I doubt a collaboration with make us rich.’ How has he come to that conclusion! Is it his/her own view (which he is totally entitled to), but it would be nice if they would justify their statement, perhaps they haven’t done their research in relation to: - VistaGen and Nuformix entering a strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. VistaGen Therapeutics maybe a small/medium pharma company who may not make us rich but, can be extremely beneficial in specialist unmet need areas. VistaGen is developing three differentiated, patent-protected, CNS product candidates for large global markets where current treatments are inadequate to address rising mental health challenges worldwide, as well as need for non-additive, non-sedating relief from pain, unwanted movement disorders and other neurological conditions besetting increasing numbers of individuals worldwide. VistaGen and Nuformix entered strategic agreement to develop novel crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection. USPTO issued Notice of Allowance for U.S. Patent Application 16/003,816 related to therapeutic use of AV-101 for treatment of dyskinesia induced by the administration of levodopa. Patent, once issued, will be in effect until at least 2034. FDA authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy The FDA has authorised Investigational New Drug (IND) application for AV-101 as a potential new treatment of dyskinesia in individuals with PD receiving levodopa therapy.
https://seekingalpha.com/pr/17915692-vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update
https://www.prnewswire.com/news-releases/vistagen-therapeutics-reports-fiscal-year-2020-results-and-provides-cns-pipeline-update-301085372.html
Does Vistagen have sufficient financial resources to positively support a collaboration/development. Hopefully, as in June 2020, the Company announced a strategic licensing deal with EverInsight for PH94B for anxiety disorders in multiple key Asian markets; VistaGen is eligible to receive up to $177M in upfront and milestone payments, in addition to royalties, including a $5M upfront payment.
https://seekingalpha.com/news/3587153-vistagen-therapeutics-reports-fy-results
I look forward to my 5* Round the World Cruise and living extremely contentedly (from my NFX profits) when I retire next year. Be patient and stay well. YB

It took centuries to dispel this myth, although, it would appear several posters on this BB may still believe it is. They may even believe that the earth is still flat and are afraid of venturing far in case they fall over the edge, despite all evidence to the contrary. Therefore, if you are going to post disparaging, disingenuous and potentially libellous comments, I would politely suggest that you at least evidence, your spurious and obfuscating comments.

Life and Business is influenced by many factors and sometimes do not always run smoothly or how we want it to. Unfortunately, at the moment this appears to be happening with NFX and they are dammed if they do and dammed if they do not. News will come at the appropriate time, although it would appear not quick enough for some who probably haven’t got the faintest idea about business acumen, especially when it comes to research development, due diligence, sensitive negotiations and timelines. Although, do they really need to know when every i has been dotted and every t has been crossed. I suppose they would say yes, as they would argue that they’ve got a couple of quid invested and need the 10% profit to go to ‘Blackpool’ (no disrespect to Blackpool as I actually love it) but other resorts are available.

Do they not also realise that there are very astute, knowledgeable, and researched contributors, who give their time and effort to enable us to make informed decisions about our investment strategy. and the disservice they give to these posters. As a Yorkshire Lad from Gods own country I can be a little forthright (although our lass says I think I am never wrong lol), I do try to base my contributions on researched evidence. Therefore, for those who read my posts titled ‘Developments are Developing’ they are aware that business/developments/progress have not ground to a halt, especially regarding Ebers. As we know a second patent (Patent CA 2892832) was granted and issued on 14/04/2020 and therefore achieved another milestone payment. Although, it was after the 2019/2020 financial year end, so may be referred to, but not included in the year end accounts. The next maintenance payment for this is due 23/11/2020.
https://www.ic.gc.ca/opic-ipo/cpd/eng/patent/2892832/summary.html?query=Nuformix+&type=basic_search

In GreggsStottie post (04 Jul 2020 23:03) he highlights: - ‘I recall speaking to Dan in May and he said there had been some delays to one of the EBERS patent applications as a result of a change to the application....they had improved the cocrystal and the amend meant a delay. The payment was due at the end of May I think.’
Greggs is quite right, although this is for the 3rd patent application (Patent CA 2908440) which is for Tranilist Compositions. The ‘Amendments & Claims’’ were submitted on 09/04/2020 and I believe we are still awaiting the final (the wheels of bureaucracy can grind very slowly) outcome.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summa

Good afternoon all. Today I received a letter from HSBC (where I have an InvestDirect account) which was titled as above, and I am not sure if the content is good or bad news.

‘You currently hold ****** shares of Tissue Regenix Group Plc (the “Company”) in your InvestDirect investment account. We are letting you know that:

Subject to approval at the General Meeting to be held on 9th June 2020, the company is proposing to subdivide its shares on the following basis:

Every existing ordinary share of GBP0.005 will be subdivided into 1 new ordinary share of GBP0.001 and 1 valueless deferred share of GBP0.004.

Effective Date: 10 June 2020.

Please Note: The deferred shares will have only negligible rights and will therefore be effectively valueless. We will not be reflecting these shares in your account.

Etc, etc.

I would like to ask; has anyone else received such notification and what are investors thoughts feelings on the announcement?

Many thanks and keep well.
YB

Obviously, this is not a Micky Mouse achievement and if they can make the necessary amendments to the 3rd (of 3) (which could be the big one?) then up, up and away! I contemplated as to whether I should have posted my original findings, (hope I have got it right) as I would not want to influence any forthcoming announcement. Also please accept my sincere apologies if I have offended anyone, except those who wish to profit at another investors expense.

Please try and ignore posters who are using very amateurish ‘Subliminal Persuasion’ techniques and keep well. YB

Thankfully, there are astute, intelligent, and extremely knowledgeable posters on this BB. Who mercifully do not get sucked into the ‘Herd/mob/pack mentality’? This means they are not influenced by their peers to adopt certain thinking/behaviours on a largely emotional, rather than rational basis. Throughout my posts I have always tried to maintain that posters should be entitled to their own views and personally try not to be critical of these or engage in debate, despite how unscrupulous they may appear to be. Though, recently I have noticed that some posts (without justification/evidence as to their validity) could be interpreted as verging on being dishonest or even immoral, I believe with the intention to influence others to get what they want.

I acknowledge that company communication has been sparse but if you do your research, as many on this BB do. You will realise that business is progressing and I agree with GreggsStottie (sorry to hear you’ve cashed out of TRX, but hey ho!) re: hey ho Fri 18:12hrs ‘We should hear about the ebers payment in the next 2 weeks, then onwards and upwards to the Kissei deal in June July hopefully.... ‘
For those who fully assimilated my post: re: Developments are Developing. 11th May 2020 12:01, (especially 2nd (of 3)) they will probably have put 2 and 2 together and got 4, realising that Dan & Co have achieved another milestone, as required by the: - ‘Ebers’ agreement (RNS Tue, 9th Apr 2019 07:00 No 5048V, Nuformix PLC – Strategic Cannabinoid Agreement): – ‘today announces it has signed an agreement for cannabinoid therapeutics development, licensing and commercialisation containing up to £51 million of upfront, R&D and milestone payments, plus long-term royalties of 20% of net sales (the "Agreement").’
‘Under the terms of the Agreement and the expected development timeline, Nuformix will receive a significant upfront payment and believes it will earn further R&D and early-stage milestone payments up to a total of £1m during 2019. Further pre-clinical and clinical milestone payments are expected in 2020 and 2021, in addition to royalty payments of 20%, given the speed to market for consumer therapeutic products.’

This was further re-enforced in: - (RNS 9th Sept 2019- No 6247L) Ebers Cannabinoid Collaboration Update:
The number of patents filed is one of several key performance indicators for the collaboration and demonstrates the partnership and overall concept are well-founded. For Nuformix, this first patent filing creates a path to further income from Ebers. We will continue to inform the market as further patents are filed and milestones and royalties are paid in-line with the agreement". ‘The patented cannabinoid forms have immediate applications in both pharmaceutical and consumer products worldwide, which in due course, will generate further milestone payments, plus royalties to Nuformix of 20% under the Agreement terms.’

To be continued

In my opinion NO and I am sure there are numerous posters in agreement. This is evidenced by the excellent, detailed, intelligent, and insightful contributions to the discussions this morning and to those please accept my sincere thanks. This means I do not have to post repetitive information/views (like several posters) to justify my NO decision. Although, it would appear that a number of posters are still believing the miss information/representation provided by unscrupulous press outlets and de-rampers.

However, one news post did catch my eye, and I am unsure whether, it has been commented on. This was towards the end of the news item: - ‘Exclusive: First coronavirus antibody test given approval by Public Health England’ The Telegraph.
‘It emerged on Wednesday that the pharmacist Boots is advertising for an army of hundreds of unpaid volunteers to test people for coronavirus. An advertisement on the company's website said it is looking for 1,000 current staff and volunteers to work at least 32 hours a week as swab testers across the UK’.
https://www.msn.com/en-gb/news/coronavirus/exclusive-first-coronavirus-antibody-test-given-approval-by-public-health-england/ar-BB142Udu
Are ‘Boots’ going to recruit ‘professional health workers’ or will they say untrained/non-professionals can carry out any anti-body test. Even though at the moment the standard is that ‘professionals health workers’ have to perform the current market testing. The Roche test is even more intricate as it requires an invasive Venepuncture procedure and will have to be undertaken by those wearing enclosed ‘PPE’? In addition, how competent will the logistics process be? Unfortunately my local Boots appear to have difficulty just organising my bi-monthly prescription!

It is very evident that we still require a ‘reliable/validated POC Home test’. I still fully believe the consortium and ODX are the ‘odds on favourites’ to develop this and therefore obtain the GOLDEN TICKET. However, those who are still dithering and sat on the fence (just hope the spikes are not too sharp) or are feeling discombobulated with the current situation. My suggestion would be ‘DON’T PANIC MR(s) INVESTOR’ and is highlighted by one of my favourite comedies: - https://www.bing.com/videos/search?q=don%27t+panic+dad%27s+army&&view=detail&mid=CD8577F8590E762C3A1CCD8577F8590E762C3A1C&&FORM=VRDGAR&ru=%2Fvideos%2Fsearch%3Fq%3Ddon%2527t%2Bpanic%2Bdad%2527s%2Barmy%26%26FORM%3DVDVVXX

Please show patience, good luck to all and stay well.
YB

Continued
You can bet your last ‘shilling’ that I am. Not only, will I make a ‘bob or two’, which is always an extremely attractive proposition for a ‘God’s Own Country’, Lad. But also, from an altruistic and personal perspective as when we are successful, this will vastly enhance the quality of life of so many people. Anything that can reduce extensive waiting for results and the associated psychological trauma will be a blessing. IMHO all the planets are aligning to produce a colossal outcome!

As the saying goes, patience is a virtue as is ‘DYOR’, good luck and stay well.
YB

This is not about Charlie and the Chocolate Factory (although I would not mind one), but the race in the UK is for, reliable, validated and approved, Covid-19 tests. The person who decides is not the eccentric chocolatier Willy Wonka, but BJ (who in the past may have been called eccentric himself) et al and the UK government.

'Crappy' tests to check for past coronavirus infection are flooding the US, lab association says: - "It's like the wild, wild West out there -- or wild East," said Scott Becker, a reference to the fact that at least half of the companies making these tests are in China.’
https://www.msn.com/en-us/news/us/crappy-tests-to-check-for-past-coronavirus-infection-are-flooding-the-us-lab-association-says/ar-BB12c01k

It is obvious that the competition is fierce in this sector to obtain the Golden Ticket and therefore, attain the UK governments and maybe the global outcome. There are some fantastic contributions to the discussion, however, some posters on this BB are posting (hopefully unintentionally) unreliable information/endorsements which I do find quite worrying. Not only from an investment but an altruistic perspective. One example is that a number may give the impression that if the ‘product’ displays a ‘CE mark’, this could imply that in some way it has received official UK approval and has been validated. Therefore, what does the CE mark mean? ‘By affixing the CE mark the Responsible Person takes on responsibility for the conformity of the product. CE marking is a visible sign that the product complies with all relevant product supply law, and its presence together with the, Declaration of Conformity, gives the product to which it is affixed presumption of conformity with relevant product safety Directives.’
‘However, the CE mark is not a quality mark, nor a guarantee that the product meets all the requirements of relevant EU product safety law.’
https://www.hse.gov.uk/work-equipment-machinery/ce-mark-summary.htm

‘The limits of testing kits: Even if a test has a CE mark, it may be of limited use.
Professor John Newton, national coordinator of the UK coronavirus (COVID-19) testing programme, has warned that some rapid tests could be misleading, by providing inaccurate or inconsistent results, potentially putting those tested and those around them at risk.’
https://www.gov.uk/guidance/guidance-on-coronavirus-covid-19-tests-and-testing-kits

Obviously, the required validation in the first instance is to achieve PHEs requirements. Therefore, (as some astute posters have already identified) no news can be good news as inflated claims can just obfuscate the situation. My limited (although I am following the science, as advised by the government) opinion, is ODX and the consortium continue to be front runners in achieving ‘PHE’ validation. Consequently, there may be a couple of ‘GTs’ up for grabs. Am I pleased that I’ve found and invested in one of the few companies with the unbelievable opportunity of holding one

Good day all. Further to my post of yesterday, I now realise that I should have included my reference for such a statement and can only apologise. I blame it on alcohol fuelled, ‘lockdown’ malady, although it prompted me to further my (already extensive) research on one of my significant investments.

So far there has been 3 patent documents submitted to the ‘Canadian Intellectual Property Office’.
https://www.ic.gc.ca/opic-cipo/cpd/eng/search/results.html?query=Nuformix
As we already know, the 1st was issued last year.
Patent CA 2846460 English Title: ‘APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL’. Applicants: NUFORMIX LIMITED (United Kingdom).
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2846460/summary.html?query=Nuformix&type=

However, most investors may not realise the 2nd (of 3) was Granted/Issued on 14/04/2020.
‘Patent CA 2892832 English Title: APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS’. Applicants: NUFORMIX LIMITED (United Kingdom).
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2892832/summary.html?query=Nuformix+&type=basic_search

The 3rd (of 3) is Application: CA 2908440 English Title: TRANILAST COMPOSITIONS AND COCRYSTALS. Applicants: NUFORMIX LIMITED (United Kingdom).
On 09/04/2020 this is still awaiting an ‘Amendment’.
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2908440/summary.html?query=Nuformix&type=
(Interestingly this is for ‘Tranilast Compositions’)

In addition to providing an update for constructive and perceptive posters, hopefully, it will also provide reassurance to the obfuscating negative posters, especially those who constantly criticise Dan and the BOD. As this indicates (during these trying times) its business as usually and valuable progress is being achieved, and I for one am not concerned, regarding the lack of formal communications from the company. As those who are professional/business savvy will know, negotiations/developments are industry sensitive and will be shared at the appropriate time. Ultimately, this should result in substantial rewards, not the few ‘pennies’ rise in SP that some investors are baying for now!

Good luck to all and stay well.
YB

Could be in the ‘East’ but perhaps look where the sun sets! Milestones equal funds, funds equal more developments and ultimately incredibly happy investors!

All the very best especially to the long-term holders who have kept the faith and stay well.
YB

Daily Mail Saturday May 9, 2020. Page 87

WHY SHOULD YOU INVEST?
John Meyer, head of research at SP Angel, said :
‘In Kenya the company operates in a remote location and is able to work through the coronavirus pandemic. And the closure of rival mines may serve to keep the market tight for some time.’
DYOR and keep well.
YB

Good afternoon B2HS2L(BH) and Walkingbear (WB) and many thanks for your posts. If I had to favour one side, it would be WB and would usually ask for the original poster (BH) to please clarify/justify their comments as to why they thought there had been non-disclosure/transparency by TRX. However, that is their personal choice, nevertheless it would appear BH comments may contradict one of his/her references posted at 00:39hrs: -

‘Go to page 6 of the above link, (AIM Rules for Companies March 2018):
General disclosure of price sensitive information
11) An AIM company must issue notification without delay of any new developments which are not public knowledge which, if made public, would be likely to lead to a significant movement in the price of its AIM securities.’

One could claim that it was placed (2017) in the ‘public domain’ (one of which is referenced) and was therefore ‘public knowledge‘ (further links are provided below), however tenuous they may appear. It was then disclosed (as previously referred to) in the company accounts, as required. However, although I am no expert, I thought I would add my ‘two-pennorth worth’ as I was a little discombobulated as to why it was ‘posted’ in the first place. The question I have is, how much transparency is enough, how much research can we perform and ultimately does this have a positive or negative impact on my continued investment!
https://www.medicaldevicesip.com/2017/05/10/lifenet-alleges-patent-infringement-against-tissue-regenix-and-community-tissue-services/
https://www.courtlistener.com/docket/6060453/lifenet-health-v-tissue-regenix-woundcare-inc/
https://dockets.justia.com/docket/texas/txwdce/5:2017cv01061/900048
https://www.pacermonitor.com/public/case/21390348/LifeNet_Health_v_Tissue_Regenix_Woundcare,_Inc_et_al

The answer to myself is, NO. Obviously, it is historic and therefore shouldn’t influence future progress and my faith has not diminished. Once funding has been secured, this will (along with one other investment) provide me with an extremely comfortable and worry-free retirement.
As they say, please, please DYOR and stay well
YB

https://www.youtube.com/watch?v=zb6j7o1pLBw
YB

Carados, excellent find and in my opinion is not just interesting, but a must watch. Obviously its quite a lengthy video, but for me intriguing in that it dismisses some of the alleged science and possible myths that are out there. Negative posters on here may not be enamoured with some of the content, as it may not fit in with their de-ramping views. However, it is extremely supportive of (not necessary ‘lab’ but ‘rapid at point of contact’) testing, which bodes extremely well for ODX and our developments.

https://www.youtube.com/watch?v=xfLVxx_lBLU&feature=youtu.be
Good luck all and keep well.
YB

Can you please justify why you posted such an obfuscating statement ‘Potentially a killer blow to ODX/Mologic if true’!

Unfortunately, I cannot find any research evidence why this would affect the company’s development/future. Therefore, I would very much appreciate being signposted to such before, I make any further decisions on my investment strategy.

I thank you in anticipation or are you just being disingenuous?

Good luck all, stay safe and keep well.
YB

Good morning SD78, unfortunately, I missed your post on 03 March 2020 17:47, but had a look back and you said:

Had a quick look back and couldn't see any conversation around this patent from 20th Feb, but apologies if I've missed it. Trying to figure out the background, but the below patent assigned to NFX was published on 20 Feb 2020. Looks like a new filing relating to their cocrystal use of Tranilast. It was filed in August last year.’

You are quite right it was a new filing in 08/2019, which appears to be the initial foundation for the Kissie collaboration. Unfortunately, the process takes time, is intense and quite rightly so, as due diligence is crucial. The 2020-02-20 Publication of WO2020035546A1 is acknowledgement/confirmation that the patent now has ‘World Rights’. Although I cannot be sure, but this may have been a contractual requirement for the ‘collaboration’ to progress.

Unfortunately, certain ‘things’ cannot be shared outside of any business negotiations due to confidential sensitivity. Obviously, this means that some shareholders become frustrated and, in some instances, disillusioned. As the saying goes ‘Rome wasn’t built in a Day’ and as I said yesterday ‘even if for some astonishing reason it does not happen, at least we retain rest of the world rights and NFX are not just a ‘one trick’ pony.’ I personally feel that NFX is my pension fund and will provide me with an extremely comfortable retirement. However, as the saying goes; patience is required and please, please do your own research. Do not just rely on the advice of investors (although there are some excellent posters) on BB’s, myself included.
Good luck all, stay safe and keep well.
YB

Fibrosis is a condition that can affect most organs of the body and fibroblast
proliferation, differentiation, and collagen synthesis are known to be key factors in the progression of
most types of fibrosis. Tranilast has been shown in-vivo to have potential beneficial effects in
numerous fibrotic conditions. Tranilast has been shown in-vivo to have potential in lung fibrosis (M.
Kato. Eur RespirJ. 2013; 42(57): 2330), kidney fibrosis (DJ Kelly,JAm Soc Nephrol. 2004; 15(10):
2619-29), cardiac fibrosis (J Martin, Cardiovasc Res. 2005; 65(3): 694-701), ocular fibrosis (M J Moon,
BMC Opthalmol. 2016; 16: 166) and liver fibrosis (M Uno, Hepatology. 2008; 48(1): 109-18.
‘[006] Given the wide range of fibrotic conditions and cancers for which tranilast could have a potential therapeutic benefit, as well as the different patient types and specific areas of the body requiring treatment, it is anticipated that patients would benefit from having multiple delivery methods for the administration of tranilast so as to best suit the patient's needs. The pharmaceutical compositions could include, for example, a solid oral dosage, a liquid oral dosage, an injectable composition, an inhalable composition, a topical composition or a transdermal composition.’
https://patents.google.com/patent/WO2020035546A1/en?inventor=Joanne+Holland&assignee=Nuformix+Limited

I hope this provides some reassurance for those few cynics amongst us and even if for some astonishing reason it does not happen. At least we retain rest of the world rights and as we all know NFX are not just a ‘one trick’ pony.

Good luck all, stay safe and keep well.
YB

The info below is the patent WO2020035546A1 and is the legal foundation for the exciting and extremely lucrative collaboration between Nuformix and Kissei Pharmaceuticals. Therefore, when the i(’s) are dotted and the t(‘s) are crossed and the signatures are drying, this will soar. Unfortunately, further patience may be required especially due to the travel restrictions etc due to the virus crisis and I’m not sure whether electronic signatures would be accepted. I have tried contacting ‘Mystic Meg’ to predict a timeline, but alas I was unsuccessful due to her socially isolating.
Crystalline tranilast salts and their pharmaceutical use
Worldwide applications
2019 WO
Application PCT/EP2019/071881 events
2018-08-14 Priority to US201862718563P
2018-08-14 Priority to US62/718,563
2019-08-14 Application filed by Nuformix Technologies Limited
2020-02-20 Publication of WO2020035546A1
(Patent Cooperation Treaty)
‘Abstract
The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.’

Tranilast has been marketed in Japan, China and South Korea by Kissei Pharmaceutical Co. Ltd, for
allergic conditions such as allergic conjunctivitis, bronchial asthma, allergic rhinitis and atopic
dermatitis, under the Rizaben® brand name for more than thirty years. More recently tranilast has
also been shown to have anti-proliferative properties. Tranilast was shown to inhibit the
proliferation of fibroblasts and suppress collagen synthesis (M. Isaji. Biochem Pharmacol. 1987; 36:
469-474) and also to inhibit the transformation of fibroblasts to myofibroblasts and their subsequent
contraction (M. Isaji. Life Sci. 1994; 55: 287-292). This additional behaviour led to tranilast gaining
additional approval for the treatment of keloids and hypertrophic scars.
[004] Over recent years many researchers have explored the anti-proliferative effects of tranilast
to assess its potential in fibrotic and cancerous conditions. Its anti-proliferative action is believed to
be due to its ability to inhibit transforming growth factor beta (TGF-ß) (H. Suzawa. Jpn J Pharmacol.
1992 Oct; 60(2): 91-96).

To be continued

When ODX and their co-collaborators produce a successful (at point of contact, not lab reliant) instant AB test. Then this will be humongous, not only fiscally for those invested, but altruistically and essential for a return to global ‘normality’. In addition, for those who have been sharing their recent clinical experiences this may be off interest.

There Are Asymptomatic Patients
‘As regards the symptoms, even if you have experienced coronavirus symptoms, you are not necessarily immune to the deadly virus. This is because until you get tested, you will never be sure if your symptoms are COVID-19 related or brought about by seasonal flu. In fact, early symptoms of COVID-19 can be easily mistaken for many types of winter bugs, including colds and flu. There are also many cases where people are COVID-19 positive, yet they do not develop any symptoms or feel unwell.
According to Dr. Li QinGyuan, while there are those infected who developed a protective antibody, they are not sure how long the protection lasts. Dr. Li is the director of pneumonia prevention and treatment at China-Japan Friendship Hospital’.
https://www.ibtimes.com/coronavirus-tips-do-you-already-have-immunity-once-youve-been-infected-2945485

For those who are interested in the science and not just the potential monetary returns that investment in ODX might bring. Then the ‘British Society for immuniology’ expands upon this: -
https://www.immunology.org/public-information/bitesized-immunology/pathogens-and-disease/immune-responses-viruses
Good luck all, stay safe and keep well.
YB

Just read the RNS and finally got my answers. Should have looked earlier and it would have saved me composing my last post. Unfortunately the RNS wasn't advertised on my web page and I only realised when I started reading the most recent posts.
GLA